Skip to content

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$635M-220%
CTO
Citius Oncology, Inc.CTOR
-$4.66M-575%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$37.44M-41.4%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$35.53M+1,050%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$117.04M+241%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$9.21M+197%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s net change in cash?
TuHURA Biosciences, Inc. (HURA) reported net change in cash of $2.68M in Q1 2026.
How has TuHURA Biosciences, Inc.'s net change in cash changed year-over-year?
TuHURA Biosciences, Inc.'s net change in cash increased by 141.6% year-over-year, from -$6.44M to $2.68M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.